Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Apr 11;12(4):57. doi: 10.1038/s41408-022-00664-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A GSEA plots showing significant enrichment of genes regulating sensitivity or resistance to VCX among transcriptome changes induced by 48 h of treatment with NTX-301 or DAC in MV4-11 cells. B Line plots showing the survival (%) of parental (Con) and TP53-knockdown (shp53) MV4-11 cells upon treatment with NTX-301 + VCX (left) or DAC + VCX (right) for 72 h. C Matrices showing the combination index (CI) values upon treatment with NTX-301+VCX or DAC + VCX for 72 h at the indicated concentrations in parental (top) and TP53-knockdown (bottom, shp53) MV4-11 cells. CI values < 1 (blue) indicate synergistic drug combination; darker blue colors are correlated with stronger the synergism, and CI values > 1 (gray) indicate no synergism. D Growth of MV4-11 tumors subcutaneously implanted into female BALB/c nude mice (n = 5 per group, eight groups) upon treatment with NTX-301 or AZA as a monotherapy or in combination with VCX. E Kaplan–Meier curves showing the survival probabilities of female NCG mice (n = 8 per group, six groups) intravenously injected with MV4-11 cells upon treatment with NTX-301 or AZA as a monotherapy or in combination with VCX. AZA azacitidine, DAC decitabine, NTX NTX-301, VCX venetoclax. *p < 0.05; **p < 0.01; ***p < 0.001.